Cedbactam-s
(Cefoperazone & Sulbactam 1g/2g Vials)
Management of Febrile Neutropenia (FN) in solid organ malignancies following chemotherapy
Method: In this study, 92 high risk FN episodes were analyzed in 72 patients with solid organ malignancies. We used Cefoperazone - Sulbactam as an initial empiric antibiotic. Piperacillin/Tazobactam or Carbapenems were added to the patients who did not respond to initial antibiotic.
Conclusion: In this study, treatment with Cefoperazone -Sulbactam as a first-line antibiotic led to satisfactory outcome with clinical improvement of > 70% in FN episodes. Cefoperazone-Sulbactam is a reasonable initial antibiotic choice for empirical therapy in high risk FN solid organ malignancies
Cefepime, Trimethoprim/Sulfamethoxazole, Nitrofurantoin, Ciprofloxacin, Amikacin and Cefoperazone + Sulbactam susceptibilities for 248 urine isolates of E. coli
| S.No. | Cefepime | Trimethoprim/ sulfamethoxazole | Nitrofurantoin | Ciprofloxacin | Amikacin | Cefoperazone |
|---|---|---|---|---|---|---|
| Sensitive | 57.2% | 12% | 57.2% | 58% | 55.6% | 70% |
Highest rate of susceptibility was found to Cefoperazone + Sulbactam
To evaluate the use of Cefoperazone/Sulbactam in the treatment of neonatal infections caused by MDR pathogens
RESULTS: There were 90 infants who received Cefoperazone/Sulbactam. Pathogens could be isolated in 41 (45.6%) of the infants. In total, 17.1% of isolated pathogens were resistant to Cefoperazone/Sulbactam. Side-effects were seen in 4 of the infants. 2 infants had cholestasis, one infant had Neutropenia and one had superinfection with candida.
CONCLUSION: Cefoperazone/Sulbactam can be used in the treatment of Nosocomial infections caused by MDR pathogens in neonates.
Cefoperazone - Sulbactam for treatment of Intra-Abdominal infections: Randomized, Open label, Parallel group study conducted at 17 centers in India
METHOD:
Comparator ẞ-lactam/ẞ-lactamase inhibitor combination
| Group | B-lactam/ẞ-lactamase inhibitor combination & Dose |
|---|---|
| A | Cefoperazone-Sulbactam (2-8 g/day) |
| B | Ceftazidime (2-6 g/day)- Amikacin (15 mg/kg/day)-Metronidazole (500 mg TID) |
RESULTS:
| Cefoperazone-Sulbactam | Ceftazidime-Amikacin Metronidazole | |
|---|---|---|
| Continued resolution of clinical signs and symptoms at the 30-day follow-up | 91.9% | 81.8% |
| Microbiologic outcomes | 92.9% | 80% |
| Incidence of treatment related adverse events | 6.5% | 16.4% |
CONCLUSION: Empirical Cefoperazone-Sulbactam monotherapy could be a useful adjunct to surgical intervention for Intra-abdominal infections.